ArticlePloS one2011
Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01830244 (Tailored Neoadjuvant Epirubicin and Cyclophosphamide), which is not on this map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer
Who cites it
60 citing papers in PubMed, 189 citations in OpenAlex.
- Amino Acid-Driven Gold Nanochaperone Platforms for Alzheimer's Therapy: A Mechanistic and Design Framework for Protein Misfolding Modulation.Molecular neurobiology · 2026Review
- Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.International journal of pharmaceutics: X · 2025Review
- In Silico and In Vitro Profiling of Honokiol and Paclitaxel-Loaded PBM Nanoparticles for Targeted Breast Cancer Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Dual-functional probe for sensitive detection of MCF-7 cells and mendelian randomization analysis of MUC1 association with multiple cancers.Scientific reports · 2025Article
- Aptamer-guided graphene oxide quantum dots for targeted suicide gene therapy in an organoid model of luminal breast cancer.Scientific reports · 2024Article
- Development, Optimization, and in vitro Evaluation of Silybin-loaded PLGA Nanoparticles and Decoration with 5TR1 Aptamer for Targeted Delivery to Colorectal Cancer Cells.AAPS PharmSciTech · 2024Article
- Utilization of nanomaterials in MRI contrast agents and their role in therapy guided by imaging.Frontiers in bioengineering and biotechnology · 2024Review
- Immobilization of azide-functionalized proteins to micro- and nanoparticles directly from cell lysate.Mikrochimica acta · 2023Article
- Nano-Delivery System of Ethanolic Extract of Propolis TargetingNanomaterials (Basel, Switzerland) · 2023Article
- Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers.Scientific reports · 2022Article
- Glycans as Targets for Drug Delivery in Cancer.Cancers · 2022Review
- Fabrication of anionic dextran-coated micelles for aptamer targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinoma.Gene therapy · 2022Article
- Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications.Cancers · 2021Review
- Targeted Nanoparticles Harboring Jasmine-Oil-Entrapped Paclitaxel for Elimination of Lung Cancer Cells.International journal of molecular sciences · 2021Article
- Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy.Frontiers in cell and developmental biology · 2021Review
- Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.International journal of molecular sciences · 2020Review
- Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes.Molecular therapy. Nucleic acids · 2020Article
- A Review of Nanotechnology for Targeted Anti-schistosomal Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- Enhancing the potency of chemotherapeutic agents by combination with bromelain and N-acetylcysteine - an in vitro study with pancreatic and hepatic cancer cells.American journal of translational research · 2020Article
- Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MUC1 protein is an attractive target for anticancer drug delivery owing to its overexpression in most adenocarcinomas. In this study, a reported MUC1 protein aptamer is exploited as the targeting agent of a nanoparticle-based drug delivery system. Paclitaxel (PTX) loaded poly (lactic-co-glycolic-acid) (PLGA) nanoparticles were formulated by an emulsion/evaporation method, and MUC1 aptamers (Apt) were conjugated to the particle surface through a DNA spacer. The aptamer conjugated nanoparticles (Apt-NPs) are about 225.3 nm in size with a stable in vitro drug release profile. Using MCF-7 breast cancer cell as a MUC1-overexpressing model, the MUC1 aptamer increased the uptake of nanoparticles into the target cells as measured by flow cytometry. Moreover, the PTX loaded Apt-NPs enhanced in vitro drug delivery and cytotoxicity to MUC1(+) cancer cells, as compared with non-targeted nanoparticles that lack the MUC1 aptamer (P<0.01). The behavior of this novel aptamer-nanoparticle bioconjugates suggests that MUC1 aptamers may have application potential in targeted drug delivery towards MUC1-overexpressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.